Vistagen completes patient enrollment in Phase 3 social anxiety trial for fasedienol

Filed May 8, 2026 · Period ending May 8, 2026 · ~1 min read

Key Changes

• high

  Last patient completed final visit in PALISADE-4, the Phase 3 trial testing fasedienol nasal spray for acute treatment of social anxiety disorder. Trial completion enables data analysis and potential regulatory submission.

  8-K: Press Release verify on EDGAR →
• high

  PALISADE-4 was a randomized, double-blind, placebo-controlled study. Completion of the controlled portion marks a key milestone in the drug development timeline.

  8-K: Press Release verify on EDGAR →